Back to search results

Observational Study for Essential Tremor and Parkinson's Disease Risk

This study is looking at people with Essential Tremor (ET) to understand who might be at risk of developing Parkinson's disease (PD). Researchers will analyze skin samples to look for a specific marker called phosphorylated alpha-synuclein (P-SYN). This marker is thought to be linked to PD. The goal is to see if finding P-SYN in the skin can help identify ET patients who are more likely to develop PD. You may be able to join if you are between 50 and 85 years old and have been diagnosed with ET for at least three years. The study aims to enroll 300 participants.

Study design
This is an observational study, meaning researchers will observe participants over time without giving any specific treatments. It plans to enroll 300 participants.
What's involved
You would participate from enrollment to the completion of the study, with measurements taken at baseline, 12 months, and 24 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment to the completion of study participation, with measurements taken at baseline, 12 months, and 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07428447

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Recruiting
Not specifiedAges 50–85Observational
CND Life Sciences
~300 participants
Updated 2026-08-25 on ClinicalTrials.gov

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quantity of P-SYN in skin
Measured over From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
+1 more outcome measured

Conditions

Essential Tremor, Movement Disorders
Essential Tremor
Essential Tremor-plus

Explore related trials

Essential Tremor

Where it's being run

4 sites across 4 states
Arizona1
Florida1
Kentucky1
Tennessee1

Who to contact

Jeannie Director of Clinical Research
[email protected]
480-434-6446 · ext. 371
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 50-85 years old
Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
Willing to participate in all study procedures
Able and willing to provide written informed consent

Exclusion

Under age 50, Over age 85
Clinical evidence of severe peripheral vascular disease
Clinically active coronary artery or cerebrovascular disease
Participant is currently on anticoagulant or dual anti-platelet therapy
Alcoholism
Allergic reaction to local anesthesia
History of or increased risk for impaired wound healing, scarring, or keloid formation
Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
History of other neurodegenerative disorder or evidence of neurological co-pathology
Abnormal DaTscan
Participant is currently receiving treatment with carbidopa-levodopa for PD
Isolated focal tremors (head, voice)
Task-specific tremor (e.g., primary writing tremor)
Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
Sudden onset and step-wise deterioration

What this trial measures

  • Quantity of P-SYN in skinFrom enrollment to completion of study participation from Baseline to Month 12 and then to Month 24

    Quantity of P-SYN in biopsies as a biomarker for disease progression

  • Rate of PhenoconversionFrom enrollment to completion of study participation from Baseline to Month 12 and then to Month 24

    Rate of phenoconversion from Essential Tremor to Parkinson's Disease over 24 months